Colonial Trust Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Colonial Trust Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.4K	Buy	61 +11	+22%	+$8.42K	﹤0.01%	355
2025 Q4	$38.8K	Hold	50	–	–	﹤0.01%	374
2025 Q3	$28.2K	Hold	50	–	–	﹤0.01%	400
2025 Q2	$26.3K	Hold	50	–	–	﹤0.01%	413
2025 Q1	$31.8K	Buy	+50	New	+$34.4K	﹤0.01%	388
2024 Q2	–	Sell	-4	Closed	-$3.85K	–	963
2024 Q1	$3.85K	Sell	4 -5	-56%	-$4.75K	﹤0.01%	733
2023 Q4	$7.91K	Buy	9 +3	+50%	+$2.47K	﹤0.01%	536
2023 Q3	$4.94K	Hold	6	–	–	﹤0.01%	609
2023 Q2	$4.31K	Hold	6	–	–	﹤0.01%	657
2023 Q1	$4.93K	Hold	6	–	–	﹤0.01%	621
2022 Q4	$4.33K	Buy	+6	New	+$4.43K	﹤0.01%	640

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Colonial Trust Advisors's REGN Position: Q1 2026 in Review

Colonial Trust Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $8.42K and bringing the position to 61 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #355.

Colonial Trust Advisors first reported a position in REGN in Q4 2022 and has held it in 11 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Colonial Trust Advisors held 61 shares of Regeneron Pharmaceuticals worth $47.4K as of Q1 2026.
Colonial Trust Advisors bought 11 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $8.42K.
Regeneron Pharmaceuticals made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q1 2026, its #355 holding.
Colonial Trust Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Colonial Trust Advisors's 13F filing for Q1 2026, filed 12 May 2026.